- Home
- CIK vs INBX Comparison
CIK vs INBX Comparison
Compare CIK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- INBX
- Stock Information
- Founded
- CIK 1987
- INBX 2010
- Country
- CIK United States
- INBX United States
- Employees
- CIK N/A
- INBX N/A
- Industry
- CIK Finance/Investors Services
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- INBX Health Care
- Exchange
- CIK Nasdaq
- INBX Nasdaq
- Market Cap
- CIK 154.6M
- INBX 178.5M
- IPO Year
- CIK N/A
- INBX 2020
- Fundamental
- Price
- CIK $2.98
- INBX $21.73
- Analyst Decision
- CIK
- INBX Hold
- Analyst Count
- CIK 0
- INBX 1
- Target Price
- CIK N/A
- INBX N/A
- AVG Volume (30 Days)
- CIK 115.4K
- INBX 120.3K
- Earning Date
- CIK 01-01-0001
- INBX 08-12-2025
- Dividend Yield
- CIK 9.03%
- INBX N/A
- EPS Growth
- CIK N/A
- INBX N/A
- EPS
- CIK N/A
- INBX 111.58
- Revenue
- CIK N/A
- INBX $200,000.00
- Revenue This Year
- CIK N/A
- INBX N/A
- Revenue Next Year
- CIK N/A
- INBX N/A
- P/E Ratio
- CIK N/A
- INBX $0.20
- Revenue Growth
- CIK N/A
- INBX N/A
- 52 Week Low
- CIK $2.50
- INBX $10.80
- 52 Week High
- CIK $3.19
- INBX $22.28
- Technical
- Relative Strength Index (RSI)
- CIK 66.81
- INBX 84.22
- Support Level
- CIK $2.96
- INBX $13.97
- Resistance Level
- CIK $2.92
- INBX $15.25
- Average True Range (ATR)
- CIK 0.03
- INBX 1.10
- MACD
- CIK 0.00
- INBX 0.66
- Stochastic Oscillator
- CIK 92.86
- INBX 95.32
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.